An experimental, orally studied angiotensin IV analog investigated in preclinical rodent and lab work for effects on memory and synapse formation through the HGF/c-Met pathway. No human trials.
Reviewed for accuracy · Last reviewed July 8, 2026Dihexa (N-hexanoic-Tyr-Ile-(6) aminohexanoic amide) is a small angiotensin IV analog studied almost entirely in preclinical rodent and in-vitro settings. The proposed mechanism is that it facilitates the hepatocyte growth factor (HGF) / c-Met system, which in animal models has been linked to hippocampal spine and synapse formation. These are research-stage findings, not established effects in people.
It is not FDA-approved and has not been through human clinical trials as dihexa itself. Reported memory and synaptogenesis effects come from rat and mouse experiments, so any statement about what it does in humans is speculative. Some early mechanism papers from the original research group have also been retracted or flagged with an expression of concern, which is a further reason to treat the evidence cautiously.
There is no established human dose for dihexa. Rodent studies used roughly 1 – 2 mg/kg orally. It is experimental and not FDA-approved, so there is no clinical dosing guidance and any human figures are anecdotal.
Read the full Dihexa dosage guide →Dihexa has no human safety data. Because its proposed HGF/c-Met target is a growth pathway, long-term risks are unstudied. All findings to date are preclinical.
Read the full Dihexa side effects guide →Handling and storage practices for dihexa are not standardized because it is a research compound without an approved product. Lab material is generally kept cool, dry, and away from light. See the full storage & safety guide for general handling and disposal basics.
This page is an independent educational reference and is not medical advice, and does not indicate any approval status for any use. Talk to a doctor before starting any compound.